Selenium: study protocols
71 study groups say how much Selenium participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
11,227 products in our catalogue print how much Selenium a serving holds.
Most common: 50 mcg to 100 mcg, 34% of 11,227 products.
| Dose per serving | Products |
|---|---|
| 5 mcg or less | 327 |
| 5 mcg to 10 mcg | 386 |
| 10 mcg to 25 mcg | 2,160 |
| 25 mcg to 50 mcg | 2,199 |
| 50 mcg to 100 mcg | 3,776 |
| 100 mcg to 250 mcg | 1,947 |
| over 250 mcg | 432 |
Dose per serving from research
71 study groups in 48 studies say how much Selenium participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 100 mcg to 250 mcg, 54% of 71 study groups.
| Daily dose | Study groups |
|---|---|
| 10 mcg or less | 3 |
| 10 mcg to 25 mcg | 1 |
| 25 mcg to 50 mcg | 6 |
| 50 mcg to 100 mcg | 15 |
| 100 mcg to 250 mcg | 38 |
| 250 mcg to 500 mcg | 6 |
| over 500 mcg | 2 |
Commonly used together
29 of 71 study groups took Selenium with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin E | 14 |
| Zinc | 9 |
| Coenzyme Q10 | 8 |
| Vitamin C | 8 |
| Beta-Carotene | 6 |
71 study groups
| Study | |||
|---|---|---|---|
| Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer 2013 · selenium 200 µg/day · Men younger than 80 with a negative prostate biopsy and at least one prostate cancer risk indicator (PSA >4 ng/ml, suspicious DRE, or PSA velocity >0.75 ng/ml/year) | 200 mcg | 154 weeks | 234 |
| The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies 2007 · group S1 · Euthyroid pregnant women positive for thyroid peroxidase antibodies (TPOAb+) | 200 mcg | — | 77 |
| Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial 2002 · selenium supplementation · Residents of the Eastern United States with a history of nonmelanoma skin cancer; age and sex not specified | 200 mcg | — | — |
| Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial 2003 · selenium supplementation · Residents of the Eastern USA at risk of recurrent nonmelanoma skin cancer; age and sex not specified | 200 mcg | — | — |
| Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial 2003 · selenium group · Patients in the Eastern United States with a history of nonmelanoma skin cancer | 200 mcg | — | — |
| Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial 2007 · selenium recipients · Mostly older adults without type 2 diabetes at baseline, recruited from dermatology clinics | 200 mcg | 2811 days | — |
| Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) 2011 · selenium group · Healthy men at average risk of prostate cancer; age 50 or older for African Americans and 55 or older for others | 200 mcg | 2008 days | — |
| Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT 2012 · selenium · Men aged 50 years or older if Black and 55 years or older otherwise, without prior prostate cancer diagnosis | 200 mcg | 6 years | — |
| Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral-naive, HIV-infected adults in Botswana: a randomized clinical trial 2013 · selenium alone · Adults aged 18 years or older, men and nonpregnant women, with asymptomatic HIV infection, CD4 count greater than 350/μL, and no prior antiretroviral therapy | 200 mcg | 2 years | — |
| Plasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT) 2014 · selenium · African-American men aged 50 years or older and non-African-American men aged 55 years or older, without specified prostate cancer at enrollment | 200 mcg | — | — |